Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of full and fragment-B of diphtheria toxin genes in Escherichia coli for generating of recombinant diphtheria vaccines

  • Shaimaa Abulmagd (Department of Research and Development, VACSERA) ;
  • Abd El-Nasser A. Khattab (Genetics and Cytology Department, National Research Centre) ;
  • Hamdallah Zedan (Microbiology and Immunology Department, Faculty of Pharmacy, Cairo University)
  • Received : 2021.08.05
  • Accepted : 2021.12.18
  • Published : 2022.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: In the present study, whole diphtheria toxin (dt) and fragment B (dtb) genes from Corynebacterium diphtheriae Park William were cloned into Escherichia coli, the purified expressed proteins were evaluated for ultimately using as a candidate vaccine. Materials and Methods: The dt and dtb genes were isolated from bacterial strain ATCC (American Type Culture Collection) no. 13812. Plasmid pET29a+ was extracted by DNA-spin TM plasmid purification kit where genes were inserted using BamHI and HindIII-HF. Cloned pET29a+dt and pET29a+dtb plasmids were transformed into E. coli BL21(DE3)PlysS as expression host. The identity of the sequences was validated by blasting the sequence (BLASTn) against all the reported nucleotide sequences in the NCBI (National Center for Biotechnology Information) GenBank. Production of proteins in high yield by different types and parameters of fermentation to determine optimal conditions. Lastly, the purified concentrated rdtx and rdtb were injected to BALB/c mice and antibody titers were detected. Results: The genetic transformation of E. coli DH5α and E. coli BL21 with the pET-29a(+) carrying the dt and dtb genes was confirmed by colony polymerase chain reaction assay and were positive to grow on Luria-Bertani/kanamycin medium. The open reading frame of dt and dtb sequences consisted of 1,600 bp and 1,000 bp, were found to be 100% identical to dt and dtb sequence of C. diphtheriae (accession number KX702999.1 and KX702993.1) respectively. The optimal condition for high cell density is fed-batch fermentation production to express the rdtx and rdtb at 280 and 240 Lf/mL, dissolved oxygen was about 24% and 22% and the dry cell weight of bacteria was 2.41 g/L and 2.18 g/L, respectively. Conclusion: This study concluded with success in preparing genetically modified two strains for the production of a diphtheria vaccine, and to reach ideal production conditions to achieve the highest productivity.

Keywords

Acknowledgement

The authors would like to thank the Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo, Egypt and the Egyptian Company for Production of Vaccines, Sera and Drugs (VACSERA), Giza, Egypt for their support.

References

  1. Wagner KS, Stickings P, White JM, et al. A review of the international issues surrounding the availability and demand for diphtheria antitoxin for therapeutic use. Vaccine 2009;28:14-20.
  2. Tchorbanov AI, Dimitrov JD, Vassilev TL. Molecular composition of diphtheria toxoid produced using semi-synthetic and meat extract-based broths. World J Microbiol Biotechnol 2004;20:211-7.
  3. Mueller JH, Miller PA. Production of diphtheric toxin of high potency (100 Lf) on a reproducible medium. J Immunol 1941;40:21-32.
  4. World Health Organization. Immunization coverage fact sheet [Internet]. Geneva: World Health Organization; 2017 [cited 2021 Jun 30]. Available from: http://www.who.int/mediacentre/factsheets/fs378/en/.
  5. Kaur J, Kumar A, Kaur J. Strategies for optimization of heterologous protein expression in E. coli: roadblocks and reinforcements. Int J Biol Macromol 2018;106:803-22.
  6. Gundinger T, Spadiut O. A comparative approach to recombinantly produce the plant enzyme horseradish peroxidase in Escherichia coli. J Biotechnol 2017;248:15-24.
  7. Huang CJ, Lin H, Yang X. Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J Ind Microbiol Biotechnol 2012;39:383-99.
  8. Tan JS, Ramanan RN, Ling TC, Shuhaimi M, Ariff AB. Enhanced production of periplasmic interferon alpha-2b by Escherichia coli using ion-exchange resin for in situ removal of acetate in the culture. Biochem Eng J 2011;58:124-32.
  9. Menzella HG. Comparison of two codon optimization strategies to enhance recombinant protein production in Escherichia coli. Microb Cell Fact 2011;10:15.
  10. Sohoni SV, Nelapati D, Sathe S, Javadekar-Subhedar V, Gaikaiwari RP, Wangikar PP. Optimization of high cell density fermentation process for recombinant nitrilase production in E. coli. Bioresour Technol 2015;188:202-8.
  11. Collins JH, Young EM. Genetic engineering of host organisms for pharmaceutical synthesis. Curr Opin Biotechnol 2018;53:191-200.
  12. Uhoraningoga A, Kinsella GK, Henehan GT, Ryan BJ. The Goldilocks approach: a review of employing design of experiments in prokaryotic recombinant protein production. Bioengineering (Basel) 2018;5:89.
  13. Oliveira C, Domingues L. Guidelines to reach high-quality purified recombinant proteins. Appl Microbiol Biotechnol 2018;102:81-92.
  14. Liu M, Feng X, Ding Y, Zhao G, Liu H, Xian M. Metabolic engineering of Escherichia coli to improve recombinant protein production. Appl Microbiol Biotechnol 2015;99:10367-77.
  15. Stainer DW, Corkill JM, Scholte MJ. Preparation and properties of diphtheria toxoids in submerged culture. 3. Development of a new semisynthetic medium. Can J Microbiol 1968;14:1155-60.
  16. Freiherr von Roman M, Koller A, von Ruden D, Berensmeier S. Improved extracellular expression and purification of recombinant Staphylococcus aureus protein A. Protein Expr Purif 2014;93:87-92.
  17. Glazyrina J, Krause M, Junne S, Glauche F, Storm D, Neubauer P. Glucose-limited high cell density cultivations from small to pilot plant scale using an enzyme-controlled glucose delivery system. N Biotechnol 2012;29:235-42.
  18. Packiam K, Ramanan RN, Ooi CW, Krishnaswamy L, Tey BT. Stepwise optimization of recombinant protein production in Escherichia coli utilizing computational and experimental approaches. Appl Microbiol Biotechnol 2020;104:3253-66.
  19. Abulmagd S, Emara M, Aziz S, El-Domany R. Evaluation and characterisation of A and B fragments of Corynebacterium diphtheriae toxin towards recombinant diphtheria vaccine. Indian J Med Microbiol 2013;31:3-9.
  20. Sambrook J, Russell DW. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2001.
  21. Mohammadi N, Mojgan B, Pakzad P, Besharat M. Cloning and expression of Corynebacterium diphtheriae toxin gene. Afr J Microbiol Res 2011;5:3018-23.
  22. Nascimento DV, Lemes EM, Queiroz JL, et al. Expression and purification of the immunogenically active fragment B of the Park Williams 8 Corynebacterium diphtheriae strain toxin. Braz J Med Biol Res 2010;43:460-6.
  23. Englard S, Seifter S. Precipitation techniques. Methods Enzymol 1990;182:285-300.
  24. Chung YJ, Lee JA, Jung MY, et al. Optimization of diphtheria toxin production by Corynebacterium diphtheriae using a casein-based medium in a fermenter. Biotechnol Bioprocess Eng 2016;21:537-43.
  25. Hayakawa S, Uchida T, Mekada E, Moynihan MR, Okada Y. Monoclonal antibody against diphtheria toxin: effect on toxin binding and entry into cells. J Biol Chem 1983;258:4311-7.
  26. Johnson N, Pickett MA, Watt PJ, Clarke IN, Heckels JE. Construction of an epitope vector utilising the diphtheria toxin B-subunit. FEMS Microbiol Lett 1997;146:91-6.
  27. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay, ELISA. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J Immunol 1972;109:129-35.
  28. Romaniuk SI, Kolybo DV, Komisarenko SV. Recombinant diphtheria toxin derivatives: perspectives of application. Russ J Bioorg Chem 2012;38:565-77.
  29. Urieto JO, Liu T, Black JH, et al. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif 2004;33:123-33.
  30. Wahby AI, El-kady E, Hamdi M. Determination of antibodies to the fragments A and B of diphtheria toxin. Egypt J Immunol 1998;6:41-8.
  31. Preneta-Blanc R, Rigsby P, Wilhelmsen ES, Tierney R, Brierley M, Sesardic D. Calibration of replacement international standards of diphtheria and tetanus toxoids for use in flocculation test. Biologicals 2008;36:315-26.
  32. Sundaran B, Rao YU, Boopathy R. Process optimization for enhanced production of diphtheria toxin by submerged cultivation. J Biosci Bioeng 2001;91:123-8.
  33. Stefan A, Conti M, Rubboli D, Ravagli L, Presta E, Hochkoeppler A. Overexpression and purification of the recombinant diphtheria toxin variant CRM197 in Escherichia coli. J Biotechnol 2011;156:245-52.
  34. Metz B, Jiskoot W, Mekkes D, et al. Quality control of routine, experimental and real-time aged diphtheria toxoids by in vitro analytical techniques. Vaccine 2007;25:6863-71.
  35. Tan JS, Ramanan RN, Azaman SN, Ling TC, Shuhaimi M, Ariff AB. Enhanced interferon-α2b production in periplasmic space of Escherichia coli through medium optimization using response surface method. Open Biotechnol J 2009;3:117-24.
  36. Volonte F, Marinelli F, Gastaldo L, et al. Optimization of glutaryl-7-aminocephalosporanic acid acylase expression in E. coli. Protein Expr Purif 2008;61:131-7.
  37. Yari K, Fatemi SS, Tavallaei M. High level expression of recombinant BoNT/A-Hc by high cell density cultivation of Escherichia coli. Bioprocess Biosyst Eng 2012;35:407-14.
  38. Ahmad I, Nawaz N, Darwesh NM, et al. Overcoming challenges for amplified expression of recombinant proteins using Escherichia coli. Protein Expr Purif 2018;144:12-8.
  39. Usuwanthim K, Pootong A, Chaisri U, et al. Murine monoclonal antibodies neutralizing the cytotoxic activity of diphtheria toxin. Asian Pac J Allergy Immunol 2008;26:47-55.
  40. McNeela EA, Jabbal-Gill I, Illum L, et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004;22:909-14.
  41. Clements CJ, Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 2002;20 Suppl 3:S24-33.
  42. Bazaral M, Goscienski PJ, Hamburger RN. Characteristics of human antibody to diphtheria toxin. Infect Immun 1973;7:130-6.
  43. Cabiaux V, Phalipon A, Wattiez R, Falmagne P, Ruysschaert JM, Kaczorek M. Expression of a biologically active diphtheria toxin fragment B in Escherichia coli. Mol Microbiol 1988;2:339-46.